Study Identifies Cathepsin L as a Dual Target for Tumor Growth and Muscle Wasting in Cancer Patients

A recent study published in *Nature Communications* identifies Cathepsin L, a lysosomal cysteine protease, as a potential dual therapeutic target for addressing tumor growth and muscle wasting in cancer patients. Researchers highlight the protein’s critical role in these processes, suggesting that targeting Cathepsin L could provide a novel approach to simultaneously combat two significant challenges faced by individuals undergoing cancer treatment.

The study outlines how Cathepsin L contributes to both tumor progression and the degradation of muscle tissue, known as cachexia, which is a common complication in cancer patients. By focusing on this single protein, researchers propose that therapies could be developed to inhibit its activity, potentially reducing tumor growth while preserving muscle mass. The findings offer new insights into the interconnected mechanisms of cancer progression and systemic effects like muscle wasting, paving the way for further exploration into targeted treatments.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

Related posts:

Study reveals that bedsores are more likely in short-staffed hospitals leaning on nurse OT, travel nurses Manufacturing Process of Glass Vials Involves Melting Silica Sand and Controlled Annealing Study Develops Dual-Layer Lattice Pads to Enhance Pressure Distribution in Wearable Technologies Rising Global Rates of Cancer, Obesity, and Diabetes Observed in Companion Animals, Livestock, and Wildlife

Author

GOAI